Page 100 - 《中国药房》2024年19期
P. 100

[ 2 ]  中国健康促进基金会,中国药学会,中国药师协会. 推进                        医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.
               药学服务体系建设和医疗保障协同发展专家共识[J]. 医                         慢性阻塞性肺疾病诊治指南:2021年修订版[J]. 中华结
               药导报,2022,41(6):755-761.                             核和呼吸杂志,2021,44(3):170-205.
               China Health Promotion Foundation,China Pharmaceuti‐  Chronic Obstructive Pulmonary Disease Group of the Re‐
               cal  Association,China  Pharmacists  Association.  Expert   spiratory Disease Branch of the Chinese Medical Associa‐
               consensus on promoting the construction of pharmaceuti‐  tion,Chronic  Obstructive  Pulmonary  Disease  Working
               cal service system and collaborative development of medi‐  Committee  of  the  Respiratory  Physicians  Branch  of  the
               cal security[J]. Her Med,2022,41(6):755-761.        Chinese Medical Doctor Association. Diagnosis and treat‐
          [ 3 ]  国家卫生健康委,国家中医药管理局 . 关于加快药学服                        ment  guidelines  for  chronic  obstructive  pulmonary  di-
               务高质量发展的意见[J].中华人民共和国国家卫生健康                          sease:revised in 2021[J]. Chin J Tuberc Respir Dis,2021,
               委员会公报,2018(11):16-18.                               44(3):170-205.
               National Health Commission,State Administration of Tra‐  [10]  王导新,熊伟,王勤,等 .《中国支气管哮喘防治指南
               ditional  Chinese  Medicine.  Opinions  on  accelerating  the   (2020年版)》评述[J]. 西部医学,2022,34(1):1-4.
               high-quality  development  of  pharmaceutical  services[J].    WANG  D  X,XIONG  W,WANG  Q,et  al.  Review  of
               Gaz  State  Counc  People’s  Repub  China,2018 (11):  Guidelines for Bronchial Asthma Prevention and Manage‐
               16-18.                                              ment (2020 Edition)[J]. Med J West China,2022,34(1):
          [ 4 ]  廖敏辉,曾平,杨西晓,等. 药学服务转型与健全医保付                        1-4.
               费体系的关系探索[J].今日药学,2020,30(10):711-714.          [11]  田塬,唐贵菊,王继婷,等. 药学服务发展历程及价值体
               LIAO M H,ZENG P,YANG X X,et al. Exploration on      现[J]. 中国药房,2021,32(23):2924-2929.
               the relationship between the transformation of pharmaceu‐  TIAN Y,TANG G J,WANG J T,et al. Development pro‐
               tical care and the improvement of medicare payment sys‐  cess  and  value  manifestation  of  pharmaceutical  care[J].
               tem[J]. Pharm Today,2020,30(10):711-714.            China Pharm,2021,32(23):2924-2929.
          [ 5 ]  Global  Initiative  for  Chronic  Obstructive  Lung  Disease.   [12]  HEPLER C D,STRAND L M. Opportunities and respon‐
               Global strategy for the diagnosis,management and preven‐  sibilities  in  pharmaceutical  care[J].  Am  J  Hosp  Pharm,
               tion of chronic obstructive pulmonary disease 2023 report   1990,47(3):533-543.
               [EB/OL]. [2024-02-19]. https://goldcopd.org/2023-gold-   [13]  REEDER  C  E.  Overview  of  pharmacoeconomics  and
               report-2/.                                          pharmaceutical  outcomes  evaluations[J].  Am  J  Health
          [ 6 ]  VENKATESAN P. 2023 GINA report for asthma[J]. Lan‐  Syst Pharm,1995,52(19 Suppl. 4):S5-S8.
               cet Respir Med,2023,11(7):589.                 [14]  临床药学服务价值评价实践指南:第一版[J].医药导报,
          [ 7 ]  江苏省药学会医院药学专业委员会,《江苏省医疗机构                          2024,43 (3):321-333.
               呼吸与危重症医学科咳喘药学服务门诊质量管理规范》                            Practice  guidelines  for  evaluating  the  value  of  clinical
               编写组. 江苏省医疗机构呼吸与危重症医学科咳喘药学                           pharmacy services:first edition[J] Med J,2024,43 (3):
               服务门诊质量管理规范[J]. 中国医院药学杂志,2023,43                     321-333.
              (9):943-949.                                    [15]  谢扬帆,张虹. 临床药学服务研究进展及发展方向[J]. 中
               Jiangsu  Pharmaceutical  Association  Hospital  Pharmacy   国卫生产业,2019,16(10):188-191,194.
               Professional Committee,The Drafting Team of the Quality   XIE Y F,ZHANG H. Research progress and development
               Management  Standards  for  Cough  and  Asthma  Pharma‐  direction  of  clinical  pharmaceutical  services[J].  China
               ceutical  Services  Outpatient  Department  of  Respiratory   Health Ind,2019,16(10):188-191,194.
               and  Critical  Care  Medicine  in  Medical  Institutions  in        [16]  周博雅,田月,韩容,等. 中国药学服务门诊开展及收费
               Jiangsu  Province.  Quality  management  standards  for   现状调查与分析[J]. 药品评价,2017,14(2):8-13.
               cough  and  asthma  pharmaceutical  services  outpatient       ZHOU B Y,TIAN Y,HAN R,et al. Status quo and analy‐
               department  of  respiratory  and  critical  care  medicine  in   sis  of  pharmacy  outpatient  services  in  China[J].  Drug
               medical  institutions  in  Jiangsu  Province[J].  Chin  J  Hosp   Eval,2017,14(2):8-13.
               Pharm,2023,43(9):943-949.                      [17]  侯继秋,张红梅,付秀娟,等. 探讨分级药学监护模式在
          [ 8 ]  连玉菲,邱学佳,杨警囡,等. 基于药物治疗管理的慢性                        COPD 患者中的实践与效果评价[J]. 实用药物与临床,
               阻塞性肺疾病患者咳喘药学门诊服务实践[J]. 中国医院                         2019,22(2):182-185.
               药学杂志,2023,43(5):555-560.                            HOU J Q,ZHANG H M,FU X J,et al. Practice and effect
               LIAN Y F,QIU X J,YANG J N,et al. Practice of cough   evaluation  of  grading  pharmaceutical  care  mode  for
               and asthma pharmacy outpatient service for patients with   COPD patients[J]. Pract Pharm Clin Remedies,2019,22
               chronic  obstructive  pulmonary  disease  based  on  medica‐  (2):182-185.
               tion therapy management[J]. Chin J Hosp Pharm,2023,43        (收稿日期:2024-04-19  修回日期:2024-08-06)
              (5):555-560.                                                                        (编辑:林 静)
          [ 9 ]  中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国


          · 2410 ·    China Pharmacy  2024 Vol. 35  No. 19                            中国药房  2024年第35卷第19期
   95   96   97   98   99   100   101   102   103   104   105